Loading clinical trials...

COMPLETEDPHASE3

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)

NCT00444925•Pfizer

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency \>= 8 per day and urgency urinary incontinence \>=1 per day

Exclusion Criteria

•Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention.
•Patients with significant hepatic and renal disease or other significant unstable diseases.
•OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

Locations (178)

Pfizer Investigational Site

Homewood, Alabama, United States

Pfizer Investigational Site

Huntsville, Alabama, United States

Pfizer Investigational Site

Mobile, Alabama, United States

Pfizer Investigational Site

Carmichael, California, United States

Pfizer Investigational Site

Orangevale, California, United States

Pfizer Investigational Site

San Diego, California, United States

Pfizer Investigational Site

Aurora, Colorado, United States

Pfizer Investigational Site

Waterbury, Connecticut, United States

Pfizer Investigational Site

Miami, Florida, United States

Pfizer Investigational Site

Wellington, Florida, United States

Key Dates

Start Date

April 1, 2007

Primary Completion Date

July 1, 2008

Completion Date

July 1, 2008

Last Updated

March 24, 2015

Enrollment

1,712

ACTUAL participants

Conditions

Overactive Bladder

Interventions

fesoterodine fumarate

DRUG

placebo

DRUG

tolterodine tartrate

DRUG

TReating Incontinence for Underlying Mental and Physical Health

NCT05362292

Urinary Incontinence, UrgeUrinary Incontinence+4 more

View study

RECRUITINGNA

INOPASE - Performance and Safety Study of a Personalised SNM System

NCT07193407

Overactive Bladder (OAB)

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Inclusion Criteria

Exclusion Criteria

TReating Incontinence for Underlying Mental and Physical Health

INOPASE - Performance and Safety Study of a Personalised SNM System

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead

BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks